Analyst Undervalued Stocks on the NAS September 2023

September 18, 2023

Analyst Undervalued

Companies on this list are considered undervalued based on the analyst consensus. This means that the average analyst target price is greater than the close price.

NASDAQ

The National Association of Securities Dealers Automated Quotations (Nasdaq) located in New York City, is the most active stock exchange by volume in the United States.

About the Data

This table includes the close price and analyst target price mean from most recent available data. The fiscal year indicates the year for the analyst target price, as the target may not always be for the current year. The number of estimates indicates the number of analyst targets used to calculate the target price mean.

How do you use this table?

Analysts believe that the companies on this list will see the close price move up to their target price mean by the target year indicated. Companies with a large analyst following or large difference between close price and target price are particularly interesting to investigate further. This becomes a starting point for further analysis to understand why these companies are undervalued. Stocks in this category are generally held for capital appreciation or dividends.

For an in-depth look at the fundamentals and valuation of each company, try the stockcalc platform free for 30 days.

SymbolNameClose PriceTarget Price MeanTarget YearNumber of EstimatesCurrency
REGN Regeneron Pharmaceuticals Inc 730.96 841.20 2023 5 USD
MELI MercadoLibre Inc 1176.23 1665.00 2023 2 USD
CHTR Charter Communications Inc 394.57 475.33 2023 3 USD
MRNA Moderna Inc 120.65 273.67 2023 3 USD
BIIB Biogen Inc 265.25 342.20 2023 5 USD
ALGN Align Technology Inc 339.85 420.00 2023 1 USD
SBAC SBA Communications Corp 226.40 318.33 2023 3 USD
ILMN Illumina Inc 191.19 273.80 2023 5 USD
ALNY Alnylam Pharmaceuticals Inc 194.94 288.00 2023 6 USD
ULTA Ulta Beauty Inc 454.74 591.50 2024 4 USD
All data provided as at market close September 14, 2023.

Company Details

Regeneron Pharmaceuticals Inc

REGN:NAS

Close Price

730.96

Target Price Mean

841.20

Target Year

2023

Target Price # Estimates

5

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis.

Access the stockcalc valuation


MercadoLibre Inc

MELI:NAS

Close Price

1176.23

Target Price Mean

1665.00

Target Year

2023

Target Price # Estimates

2

MercadoLibre runs the largest e-commerce marketplace in Latin America, connecting a network of more than 148 million active users and 1 million active sellers as of the end of 2022 across an 18-country footprint.

Access the stockcalc valuation


Charter Communications Inc

CHTR:NAS

Close Price

394.57

Target Price Mean

475.33

Target Year

2023

Target Price # Estimates

3

Charter is the product of the 2016 merger of three cable companies, each with a decades-long history in the business: Legacy Charter, Time Warner Cable, and Bright House Networks. The firm now holds networks capable of providing television, internet access, and phone services to roughly 56 million U.S. homes and businesses, around 40% of the country.

Access the stockcalc valuation


Moderna Inc

MRNA:NAS

Close Price

120.65

Target Price Mean

273.67

Target Year

2023

Target Price # Estimates

3

Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 44 mRNA development programs as of early 2022, with 25 of these in clinical trials. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.

Access the stockcalc valuation


Access our valuation for these companies and 9,000+ more

Try the stockcalc platform free for 30 days

Sign Up

Biogen Inc

BIIB:NAS

Close Price

265.25

Target Price Mean

342.20

Target Year

2023

Target Price # Estimates

5

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel multiple sclerosis drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is copromoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with Sobi) were spun off as part of Bioverativ in 2017.

Access the stockcalc valuation


Align Technology Inc

ALGN:NAS

Close Price

339.85

Target Price Mean

420.00

Target Year

2023

Target Price # Estimates

1

Align Technology is the leading manufacturer of clear aligners. Invisalign, its main product, was approved by the FDA in 1998, and it has since dominated, controlling over 90% of the market. Invisalign can treat roughly 90% of all malocclusion cases (misaligned teeth), and there are over 230,000 Invisalign-trained dentists and orthodontists.

Access the stockcalc valuation


SBA Communications Corp

SBAC:NAS

Close Price

226.40

Target Price Mean

318.33

Target Year

2023

Target Price # Estimates

3

SBA Communications owns and operates almost 40,000 cell towers throughout North America, South America, and Africa. It leases space on its towers to wireless service providers, who install equipment on the towers to support their wireless networks. The company has a very concentrated customer base, with most revenue in each market being generated by just the top few mobile carriers. The company owns more than 17,000 towers in the U.S.

Access the stockcalc valuation


Illumina Inc

ILMN:NAS

Close Price

191.19

Target Price Mean

273.80

Target Year

2023

Target Price # Estimates

5

Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening.

Access the stockcalc valuation


Alnylam Pharmaceuticals Inc

ALNY:NAS

Close Price

194.94

Target Price Mean

288.00

Target Year

2023

Target Price # Estimates

6

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.

Access the stockcalc valuation


Ulta Beauty Inc

ULTA:NAS

Close Price

454.74

Target Price Mean

591.50

Target Year

2024

Target Price # Estimates

4

With 1,355 stores at the end of fiscal 2022 and a partnership with Target, Ulta Beauty is the largest specialized beauty retailer in the U.S. The firm offers makeup (42% of 2022 sales), fragrances, skin care, and hair care products (21% of 2022 sales), and bath and body items. Ulta offers private-label products and merchandise from more than 500 vendors. It also offers salon services, including hair, makeup, skin, and brow services, in all stores.

Access the stockcalc valuation


Access thousands of valuation reports

Try the stockcalc platform for 30 days for unlimited access to our valuation reports

Sign Up
Regeneron Pharmaceuticals and MercadoLibre are among the most undervalued NAS stocks this month. See the most undervalued companies on the blog: https://www.stockcalc.com/Blog/analyst-undervalued-stocks-nas-september-2023
Regeneron Pharmaceuticals $REGN and MercadoLibre $MELI on the #NAS among the most undervalued this month. See the full list of undervalued companies: https://www.stockcalc.com/Blog/analyst-undervalued-stocks-nas-september-2023
Regeneron Pharmaceuticals and MercadoLibre are among the most undervalued NAS stocks this month. See the most undervalued companies on the blog: https://www.stockcalc.com/Blog/analyst-undervalued-stocks-nas-september-2023

Copyright © 2016- Patchell Brook Equity Analytics Inc. All rights reserved.

Risk Disclosure: Equities trading and trading of all markets, exchanges and instruments contains substantial risk and is not for every investor. An investor could potentially lose all or more than the initial investment. Risk capital is money that can be lost without jeopardizing ones’ financial security or life style. Only risk capital should be used for trading and only those with sufficient risk capital should consider trading. Past performance is not necessarily indicative of future results. View full risk information here.